Public Employees Retirement System Of Ohio Iovance Biotherapeutics, Inc. Transaction History

Public Employees Retirement System Of Ohio

$25.2 Billion
Q2 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Dec 19, 2023	BUY	$5.53 - $8.22 $324,190 - $481,889	58,624 Added 242.19%	82,830 $506,000
Q1 2023 May 15, 2023	BUY	$5.53 - $8.22 $324,190 - $481,889	58,624 Added 242.19%	82,830 $506,000
Q4 2022 Dec 19, 2023	BUY	$5.62 - $10.0 $136,037 - $242,060	24,206 New	24,206 $154,000
Q4 2022 Feb 15, 2023	SELL	$5.62 - $10.0 $30,876 - $54,940	-5,494 Reduced 18.5%	24,206 $155,000
Q3 2022 Nov 15, 2022	BUY	$9.53 - $13.11 $283,041 - $389,367	29,700 New	29,700 $285,000
Q2 2022 Aug 15, 2022	SELL	$6.38 - $18.33 $494,213 - $1.42 Million	-77,463 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$12.38 - $19.1 $34,490 - $53,212	-2,786 Reduced 3.47%	77,463 $1.29 Million
Q4 2021 Feb 15, 2022	SELL	$16.55 - $27.63 $32,620 - $54,458	-1,971 Reduced 2.4%	80,249 $1.53 Million
Q3 2021 Nov 15, 2021	SELL	$20.35 - $26.63 $13,573 - $17,762	-667 Reduced 0.8%	82,220 $2.03 Million
Q2 2021 Aug 16, 2021	BUY	$16.33 - $33.07 $158,596 - $321,175	9,712 Added 13.27%	82,887 $2.16 Million
Q1 2021 May 14, 2021	BUY	$28.67 - $52.59 $156,968 - $287,930	5,475 Added 8.09%	73,175 $2.32 Million
Q4 2020 Feb 12, 2021	BUY	$28.04 - $50.26 $365,277 - $654,737	13,027 Added 23.83%	67,700 $3.14 Million
Q3 2020 Nov 16, 2020	BUY	$27.75 - $36.3 $85,553 - $111,912	3,083 Added 5.98%	54,673 $1.8 Million
Q2 2020 Aug 17, 2020	BUY	$27.21 - $41.0 $1.4 Million - $2.12 Million	51,590 New	51,590 $1.42 Million

Others Institutions Holding IOVA

# of Institutions

320

Shares Held

238M

Call Options Held

1.27M

Put Options Held

1.68M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.74B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Public Employees Retirement System Of Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Public Employees Retirement System Of Ohio with notifications on news.

Account